Jia Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jia Deng has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Dongxin Tang
Department of Oncology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China
3 shared publications - Bing Yang
Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China
2 shared publications - Huili Shui
Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China
2 shared publications - Wenyu Wu
Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China
2 shared publications - Zhenming Xie
Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China
2 shared publications Bing Yang
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 24 (September) , 1-14
The burden of bladder cancer and kidney cancer attributable to smoking in Latin America and the Caribbean from 1990 to 2023 and projections to 2050
Introduction: Tobacco smoking is a major modifiable risk factor for bladder and kidney cancer. In Latin America and the Caribbean (LAC), comprehensive longitudinal evidence on the smoking-attributable burden of these cancers remains limited. This study assessed the burden, temporal trends,...
- 8 September 2026
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 24 (September) , 1-14
Open AccessThe burden of bladder cancer and kidney cancer attributable to smoking in Latin America and the Caribbean from 1990 to 2023 and projections to 2050
Introduction: Tobacco smoking is a major modifiable risk factor for bladder and kidney cancer. In Latin America and the Caribbean (LAC), comprehensive longitudinal evidence on the smoking-attributable burden of these cancers remains limited. This study assessed the burden, temporal trends,...
- Open Access
- 18 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (6) , 12711-12719
Efficacy and safety of HSK16149 for postoperative pain in Chinese patients after orthopedic surgery: a phase 2 randomized clinical trial
Importance: Some Chinese patients undergoing orthopedic surgery may require more effective and safer analgesics to adequately relieve moderate to severe postoperative pain. Objective: To evaluate the efficacy and safety of crisugabalin (HSK16149), a calcium channel α2δ subunit ligand oral capsule, in managing postoperative pain in Chinese patients undergoing orthopedic surgery. Methods: This Phase 2 trial was conducted from 8 March to 5 July 2023, across 20 clinical hospitals in China and employed a double-blind, randomized design, which enrolled Chinese patients scheduled for elective orthopedic surgery under general anesthesia. Patients were randomized 1:1:1:1:1 to receive HSK16149, 40 mg twice before surgery (80 mg used in total), 60 mg twice (120 mg used in total), 40 mg four times before and after surgery (160 mg used in total), 60 mg four times (240 mg used in total), and receive placebo four times before and after surgery. The primary outcome was the total morphine dose within the 24-hour postoperative period, including usage from the patient-controlled analgesia device and any additional remedial analgesia. Results: A total of 24 patients were excluded from the analysis, resulting in 235 participants randomized into the following groups: 80 mg ( n = 47), 120 mg ( n = 47), 160 mg ( n = 48), 240 mg ( n = 46), and placebo ( n = 47). Total morphine consumption within 24 hours post-surgery was significantly lower in the HSK16149 groups compared to the placebo group (Kruskal–Wallis test, P = 0.048). The means (SD) of morphine consumption were 11.00 (7.59) for the 80 mg group, 9.94 (8.15) for the 120 mg group, 10.28 (8.80) for the 160 mg group, 9.72 (10.07) for the 240 mg group, and 15.66 (12.13) for the placebo group. The P values calculated from the Wilcoxon rank sum test comparing the four HSK16149 groups to the placebo were 0.0824, 0.0239, 0.0261, and 0.0076, respectively. Conclusions: HSK16149 capsules reduced postoperative opioid consumption in Chinese patients undergoing orthopedic surgery, showing that receiving 240 mg HSK16149 was recommended and appeared to be well tolerated.
- 18 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (6) , 12711-12719
Open AccessEfficacy and safety of HSK16149 for postoperative pain in Chinese patients after orthopedic surgery: a phase 2 randomized clinical trial
Importance: Some Chinese patients undergoing orthopedic surgery may require more effective and safer analgesics to adequately relieve moderate to severe postoperative pain. Objective: To evaluate the efficacy and safety of crisugabalin (HSK16149), a calcium channel α2δ subunit ligand oral capsule, in managing postoperative pain in Chinese patients undergoing orthopedic surgery. Methods: This Phase 2 trial was conducted from 8 March to 5 July 2023, across 20 clinical hospitals in China and employed a double-blind, randomized design, which enrolled Chinese patients scheduled for elective orthopedic surgery under general anesthesia. Patients were randomized 1:1:1:1:1 to receive HSK16149, 40 mg twice before surgery (80 mg used in total), 60 mg twice (120 mg used in total), 40 mg four times before and after surgery (160 mg used in total), 60 mg four times (240 mg used in total), and receive placebo four times before and after surgery. The primary outcome was the total morphine dose within the 24-hour postoperative period, including usage from the patient-controlled analgesia device and any additional remedial analgesia. Results: A total of 24 patients were excluded from the analysis, resulting in 235 participants randomized into the following groups: 80 mg ( n = 47), 120 mg ( n = 47), 160 mg ( n = 48), 240 mg ( n = 46), and placebo ( n = 47). Total morphine consumption within 24 hours post-surgery was significantly lower in the HSK16149 groups compared to the placebo group (Kruskal–Wallis test, P = 0.048). The means (SD) of morphine consumption were 11.00 (7.59) for the 80 mg group, 9.94 (8.15) for the 120 mg group, 10.28 (8.80) for the 160 mg group, 9.72 (10.07) for the 240 mg group, and 15.66 (12.13) for the placebo group. The P values calculated from the Wilcoxon rank sum test comparing the four HSK16149 groups to the placebo were 0.0824, 0.0239, 0.0261, and 0.0076, respectively. Conclusions: HSK16149 capsules reduced postoperative opioid consumption in Chinese patients undergoing orthopedic surgery, showing that receiving 240 mg HSK16149 was recommended and appeared to be well tolerated.
- Open Access
- 14 January 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e82839
Effectiveness of Machine Learning in Detecting Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis
Background: Vessels encapsulating tumor clusters (VETC) are significantly associated with poor prognosis in hepatocellular carcinoma (HCC). However, identifying VETC early remains challenging. Recently, machine learning has shown promise for VETC detection, but their diagnostic accuracy lacks systematic validation. Objective: This meta-analysis aimed to systematically evaluate the diagnostic accuracy of machine learning models for detecting VETC in patients with HCC. Methods: The Cochrane Library, Embase, Web of Science, and PubMed were searched up to June 21, 2025. Eligible studies focused on machine learning models for HCC VETC diagnosis. Studies that merely analyzed risk factors or lacked outcome measures were excluded. The Prediction Model Risk of Bias Assessment Tool was used to evaluate the risk of bias. A bivariate mixed-effects model was used for a meta-analysis based on 2×2 diagnostic tables. Subgroup analyses were performed according to modeling variables (nonradiomic vs radiomic features) and model types (traditional machine learning vs deep learning). Results: This meta-analysis included 31 studies comprising 6755 patients with HCC (2699 VETC-positive). Nineteen studies used machine learning models based on nonradiomic features, and 12 used radiomic features (including deep learning). In the validation set, the nonradiomic model demonstrated a pooled sensitivity of 0.72 (95% CI 0.66-0.78), specificity of 0.74 (95% CI 0.68-0.80), and an area under the summary receiver operating characteristic curve (SROC AUC) of 0.80 (95% CI 0.76-0.83). The radiomic model showed sensitivity of 0.81 (95% CI 0.73-0.87), specificity of 0.73 (95% CI 0.67-0.79), and SROC AUC of 0.84 (95% CI 0.80-0.87). Traditional machine learning achieved sensitivity of 0.84 (95% CI 0.71-0.92), specificity of 0.75 (95% CI 0.67-0.81), and SROC AUC of 0.83 (95% CI 0.80-0.86). Deep learning exhibited sensitivity of 0.77 (95% CI 0.69-0.84), specificity of 0.70 (95% CI 0.59-0.79), and SROC AUC of 0.81 (95% CI 0.77-0.85). Conclusions: This meta-analysis is the first to quantitatively assess the efficacy of machine learning models in HCC VETC diagnosis, addressing an evidence gap in this field. Unlike previous descriptive reviews, this analysis provides the first quantitative evidence revealing the potential value of machine learning in detecting HCC VETC. The findings provide a foundation for developing and refining subsequent intelligent detection tools. Despite their promising prospects, machine learning models have not yet reached the maturity required for clinical translation, owing to methodological heterogeneity, limited validation, and a high risk of bias. Future research should focus on conducting multicenter, large-sample, standardized, prospective studies to advance clinical translation. Trial Registration: PROSPERO CRD420251084894; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251084894
- 14 January 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e82839
Open AccessEffectiveness of Machine Learning in Detecting Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis
Background: Vessels encapsulating tumor clusters (VETC) are significantly associated with poor prognosis in hepatocellular carcinoma (HCC). However, identifying VETC early remains challenging. Recently, machine learning has shown promise for VETC detection, but their diagnostic accuracy lacks systematic validation. Objective: This meta-analysis aimed to systematically evaluate the diagnostic accuracy of machine learning models for detecting VETC in patients with HCC. Methods: The Cochrane Library, Embase, Web of Science, and PubMed were searched up to June 21, 2025. Eligible studies focused on machine learning models for HCC VETC diagnosis. Studies that merely analyzed risk factors or lacked outcome measures were excluded. The Prediction Model Risk of Bias Assessment Tool was used to evaluate the risk of bias. A bivariate mixed-effects model was used for a meta-analysis based on 2×2 diagnostic tables. Subgroup analyses were performed according to modeling variables (nonradiomic vs radiomic features) and model types (traditional machine learning vs deep learning). Results: This meta-analysis included 31 studies comprising 6755 patients with HCC (2699 VETC-positive). Nineteen studies used machine learning models based on nonradiomic features, and 12 used radiomic features (including deep learning). In the validation set, the nonradiomic model demonstrated a pooled sensitivity of 0.72 (95% CI 0.66-0.78), specificity of 0.74 (95% CI 0.68-0.80), and an area under the summary receiver operating characteristic curve (SROC AUC) of 0.80 (95% CI 0.76-0.83). The radiomic model showed sensitivity of 0.81 (95% CI 0.73-0.87), specificity of 0.73 (95% CI 0.67-0.79), and SROC AUC of 0.84 (95% CI 0.80-0.87). Traditional machine learning achieved sensitivity of 0.84 (95% CI 0.71-0.92), specificity of 0.75 (95% CI 0.67-0.81), and SROC AUC of 0.83 (95% CI 0.80-0.86). Deep learning exhibited sensitivity of 0.77 (95% CI 0.69-0.84), specificity of 0.70 (95% CI 0.59-0.79), and SROC AUC of 0.81 (95% CI 0.77-0.85). Conclusions: This meta-analysis is the first to quantitatively assess the efficacy of machine learning models in HCC VETC diagnosis, addressing an evidence gap in this field. Unlike previous descriptive reviews, this analysis provides the first quantitative evidence revealing the potential value of machine learning in detecting HCC VETC. The findings provide a foundation for developing and refining subsequent intelligent detection tools. Despite their promising prospects, machine learning models have not yet reached the maturity required for clinical translation, owing to methodological heterogeneity, limited validation, and a high risk of bias. Future research should focus on conducting multicenter, large-sample, standardized, prospective studies to advance clinical translation. Trial Registration: PROSPERO CRD420251084894; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251084894
- Open Access
- 22 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Effectiveness of Machine Learning in Detecting Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis (Preprint)
BACKGROUND Vessels encapsulating tumor clusters (VETC) are significantly associated with poor prognosis in hepatocellular carcinoma (HCC). However, identifying VETC early remains challenging. Recently, machine learning has shown promise for VETC detection, but their diagnostic accuracy lacks systematic validation. OBJECTIVE This meta-analysis aimed to systematically evaluate the diagnostic accuracy of machine learning models for detecting VETC in patients with HCC. METHODS The Cochrane Library, Embase, Web of Science, and PubMed were searched up to June 21, 2025. Eligible studies focused on machine learning models for HCC VETC diagnosis. Studies that merely analyzed risk factors or lacked outcome measures were excluded. The Prediction Model Risk of Bias Assessment Tool was used to evaluate the risk of bias. A bivariate mixed-effects model was used for a meta-analysis based on 2×2 diagnostic tables. Subgroup analyses were performed according to modeling variables (nonradiomic vs radiomic features) and model types (traditional machine learning vs deep learning). RESULTS This meta-analysis included 31 studies comprising 6755 patients with HCC (2699 VETC-positive). Nineteen studies used machine learning models based on nonradiomic features, and 12 used radiomic features (including deep learning). In the validation set, the nonradiomic model demonstrated a pooled sensitivity of 0.72 (95% CI 0.66-0.78), specificity of 0.74 (95% CI 0.68-0.80), and an area under the summary receiver operating characteristic curve (SROC AUC) of 0.80 (95% CI 0.76-0.83). The radiomic model showed sensitivity of 0.81 (95% CI 0.73-0.87), specificity of 0.73 (95% CI 0.67-0.79), and SROC AUC of 0.84 (95% CI 0.80-0.87). Traditional machine learning achieved sensitivity of 0.84 (95% CI 0.71-0.92), specificity of 0.75 (95% CI 0.67-0.81), and SROC AUC of 0.83 (95% CI 0.80-0.86). Deep learning exhibited sensitivity of 0.77 (95% CI 0.69-0.84), specificity of 0.70 (95% CI 0.59-0.79), and SROC AUC of 0.81 (95% CI 0.77-0.85). CONCLUSIONS This meta-analysis is the first to quantitatively assess the efficacy of machine learning models in HCC VETC diagnosis, addressing an evidence gap in this field. Unlike previous descriptive reviews, this analysis provides the first quantitative evidence revealing the potential value of machine learning in detecting HCC VETC. The findings provide a foundation for developing and refining subsequent intelligent detection tools. Despite their promising prospects, machine learning models have not yet reached the maturity required for clinical translation, owing to methodological heterogeneity, limited validation, and a high risk of bias. Future research should focus on conducting multicenter, large-sample, standardized, prospective studies to advance clinical translation. CLINICALTRIAL PROSPERO CRD420251084894; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251084894
- 22 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEffectiveness of Machine Learning in Detecting Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis (Preprint)
BACKGROUND Vessels encapsulating tumor clusters (VETC) are significantly associated with poor prognosis in hepatocellular carcinoma (HCC). However, identifying VETC early remains challenging. Recently, machine learning has shown promise for VETC detection, but their diagnostic accuracy lacks systematic validation. OBJECTIVE This meta-analysis aimed to systematically evaluate the diagnostic accuracy of machine learning models for detecting VETC in patients with HCC. METHODS The Cochrane Library, Embase, Web of Science, and PubMed were searched up to June 21, 2025. Eligible studies focused on machine learning models for HCC VETC diagnosis. Studies that merely analyzed risk factors or lacked outcome measures were excluded. The Prediction Model Risk of Bias Assessment Tool was used to evaluate the risk of bias. A bivariate mixed-effects model was used for a meta-analysis based on 2×2 diagnostic tables. Subgroup analyses were performed according to modeling variables (nonradiomic vs radiomic features) and model types (traditional machine learning vs deep learning). RESULTS This meta-analysis included 31 studies comprising 6755 patients with HCC (2699 VETC-positive). Nineteen studies used machine learning models based on nonradiomic features, and 12 used radiomic features (including deep learning). In the validation set, the nonradiomic model demonstrated a pooled sensitivity of 0.72 (95% CI 0.66-0.78), specificity of 0.74 (95% CI 0.68-0.80), and an area under the summary receiver operating characteristic curve (SROC AUC) of 0.80 (95% CI 0.76-0.83). The radiomic model showed sensitivity of 0.81 (95% CI 0.73-0.87), specificity of 0.73 (95% CI 0.67-0.79), and SROC AUC of 0.84 (95% CI 0.80-0.87). Traditional machine learning achieved sensitivity of 0.84 (95% CI 0.71-0.92), specificity of 0.75 (95% CI 0.67-0.81), and SROC AUC of 0.83 (95% CI 0.80-0.86). Deep learning exhibited sensitivity of 0.77 (95% CI 0.69-0.84), specificity of 0.70 (95% CI 0.59-0.79), and SROC AUC of 0.81 (95% CI 0.77-0.85). CONCLUSIONS This meta-analysis is the first to quantitatively assess the efficacy of machine learning models in HCC VETC diagnosis, addressing an evidence gap in this field. Unlike previous descriptive reviews, this analysis provides the first quantitative evidence revealing the potential value of machine learning in detecting HCC VETC. The findings provide a foundation for developing and refining subsequent intelligent detection tools. Despite their promising prospects, machine learning models have not yet reached the maturity required for clinical translation, owing to methodological heterogeneity, limited validation, and a high risk of bias. Future research should focus on conducting multicenter, large-sample, standardized, prospective studies to advance clinical translation. CLINICALTRIAL PROSPERO CRD420251084894; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251084894